Johnson & Johnson (NYSE:JNJ) Shares Sold by Aspen Investment Management Inc

Aspen Investment Management Inc decreased its stake in Johnson & Johnson (NYSE:JNJ) by 11.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,711 shares of the company’s stock after selling 1,436 shares during the quarter. Aspen Investment Management Inc’s holdings in Johnson & Johnson were worth $1,549,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Mattern Capital Management LLC raised its position in shares of Johnson & Johnson by 4.1% in the 4th quarter. Mattern Capital Management LLC now owns 51,095 shares of the company’s stock valued at $7,389,000 after purchasing an additional 2,031 shares in the last quarter. ING Groep NV increased its stake in shares of Johnson & Johnson by 58.5% in the fourth quarter. ING Groep NV now owns 524,810 shares of the company’s stock worth $75,898,000 after buying an additional 193,689 shares during the last quarter. Flossbach Von Storch SE grew its holdings in Johnson & Johnson by 0.4% during the 4th quarter. Flossbach Von Storch SE now owns 6,529,296 shares of the company’s stock worth $944,267,000 after acquiring an additional 28,814 shares in the last quarter. Morningstar Investment Management LLC increased its position in shares of Johnson & Johnson by 5.5% in the 4th quarter. Morningstar Investment Management LLC now owns 5,855 shares of the company’s stock worth $847,000 after purchasing an additional 303 shares during the last quarter. Finally, First Bank & Trust bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $936,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JNJ shares. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup decreased their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Up 1.7 %

JNJ stock opened at $162.35 on Monday. The stock has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a 50-day moving average of $148.93 and a two-hundred day moving average of $155.86. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the previous year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.